Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.

2 Under-the-Radar Biotech Stocks to Buy in 2023

10:11am, Wednesday, 05'th Apr 2023
CRISPR Therapeutics' near-term outlook is quite bullish. There are more lucrative opportunities for Exelixis in the near future.
Hedge fund Farallon Capital Management plans to launch a proxy fight at cancer-drug maker Exelixis Inc. EXEL, +0.36% , and has nominated three directors to that company's board, the Wall Street Journa
Farallon has nominated three directors to the board of Exelixis, which develops cancer-fighting drugs.

2 Incredible Stocks to Buy With Less Than $25

10:00am, Tuesday, 04'th Apr 2023
Exelixis develops cancer drugs, a strategy that should continue to breed success. Adyen helps facilitate e-commerce across borders and is investing in its future.
It has been an eventful start to the week for investors of genomics-based drug discovery outfit Exelixis (US:EXEL), after the company announced a share buyback worth $550 million pre-market and receiv
The biotech announced a shareholder-pleasing bit of financial engineering. This will total as much as $550 million by the end of this year.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, M

2 Stocks to Buy With Less Than $20

10:07am, Friday, 10'th Mar 2023
Exelixis' exciting oncology platform can lead to new products and higher revenue. Snap's popularity among younger users remains a major long-term tailwind.
Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).
Exelixis has strong revenue growth and a positive outlook. Past success with a growing industry ensures demand for its products.
Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.
These companies could grow in prominence in the coming years.
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street esti
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE